ライフサイエンスコーパス: international normalized ratio

1 etransplant cerebral edema and postoperative international normalized ratio.

2 atients underwent ablation under therapeutic international normalized ratio.

3 farin and warfarin can be monitored with the international normalized ratio.

4 3 patients were on warfarin with therapeutic international normalized ratio.

5 sEPCR levels mirrored changes in values for international normalized ratios.

6 x (creatinine(-0.836) ) x (urea(-0.229) ) x (international normalized ratio(-0.113) ) x (age(-0.129)

7 x (creatinine(-0.836) ) x (urea(-0.229) ) x (international normalized ratio(-0.113) ) x (age(-0.129))

8 to compare the efficacy of warfarin (target international normalized ratio 1.5 to 2.5 IU) plus aspir

9 tinine (0.8 and 3.0 mg/dL, respectively) and international normalized ratio (1 and 3, respectively).

10 lt using cutoff values of 2.2 or greater for international normalized ratio (1 point) and less than 1

11 Bilirubin (1.8 vs 2.2 mg/dL; P = .032) and international normalized ratio (1.4 vs 1.5; P = .022) in

12 cipients, postoperative days 7 and 14 median international normalized ratio (1.5 and 1.2, respectivel

13 r compared with RL recipients (7 and 14 days international normalized ratio [1.2, P < 0.001; 1.1, P =

14 , 0.378 vs 0.939 [95% CI, 0.91-0.97]; log(e) international normalized ratio, 1.120 vs 1.658 [95% CI,

15 y with either adjusted-dose warfarin (target international normalized ratio 2 to 3) or fixed-dose xim

16 ns for high-risk patients (warfarin therapy, international normalized ratio 2.0 to 3.0) and low-risk

17 ned warfarin, the time in therapeutic range (international normalized ratio 2.0 to 3.0) was 62% and 6

18 as well-controlled, adjusted-dose warfarin (international normalized ratio 2.0 to 3.0).

19 errupted vitamin K antagonist phenprocoumon (international normalized ratio, 2-3).

20 evice (n = 463) or warfarin (n = 244; target international normalized ratio, 2-3).

21 e of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 pa

22 racranial artery to receive warfarin (target international normalized ratio, 2.0 to 3.0) or aspirin (

23 Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0); dabigatran,

24 r at least 6 months on oral anticoagulation (international normalized ratio, 2.0-3.0).

25 e morning after surgery, or warfarin (target international normalized ratio, 2.5 [range, 1.8 to 3.0])

26 risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (

27 arallel controls (percentage of out-of-range international normalized ratios 31% versus 42% at 1 mont

28 Among patients with abnormal international normalized ratios, 33% received fresh-froz

29 usions were all independent risk factors for international normalized ratio abnormalities (all p < .0

30 Most international normalized ratio abnormalities were minor

31 lanine transaminase, aspartate transaminase, international normalized ratio, acute kidney injury, sep

32 k aspartate transaminase, day 5 bilirubin or international normalized ratio after transplant.

33 nction, stroke, prior major bleeding, labile international normalized ratios, age 65 years or older,

34 l Organ Failure Assessment score, and higher international normalized ratio (all p</=0.001).

35 easure of synthetic liver function, based on international normalized ratio and albumin and bilirubin

36 s of bleeding and laboratory measurements of international normalized ratio and factor levels.

37 MELD assigns lower weight to creatinine and international normalized ratio and higher weight to bili

38 quiring regular laboratory monitoring of the international normalized ratio and intermittent adjustme

39 The results showed that height, target international normalized ratio and VKORC1 and CYP2C9 gen

40 F is a continuous score, based on bilirubin, international normalized ratio, and alanine aminotransfe

41 r liver function, anticonvulsant use, labile international normalized ratio, and antihypertensive use

42 ctioned, and serum transaminases, bilirubin, international normalized ratio, and lactate levels corre

43 seline levels of bilirubin, prothrombin time/international normalized ratio, and Model for End-Stage

44 ic biosynthetic capacity, such as albumin or international normalized ratio, and positively with non-

45 the 4 variables (ie, bilirubin, creatinine, international normalized ratio, and sodium) had a modest

46 antly lower blood ammonia, prothrombin time, international normalized ratio, and TGF-beta1 levels whe

47 onal status, serum albumin, serum bilirubin, international normalized ratio, and the presence of asci

48 with higher creatinine and bilirubin levels, international normalized ratio, and viral load.

49 In this study, we validated the admission international normalized ratio as an independent risk fa

50 Only recipient's age and elevated international normalized ratio at LT were associated wit

51 tients had significantly lower bilirubin and international normalized ratio at waitlisting, and less

52 ary outcomes were percentage of out-of-range international normalized ratios at 1 and 3 months and pe

53 erior to PG-1 for percentage of out-of-range international normalized ratios at 1 month and 3 months

54 At the index event, the international normalized ratio averaged 1.67 +/- 0.53, a

55 utcomes after trauma and compared two common international normalized ratio-based definitions for acu

56 e (for an individual patient) to maintain an international normalized ratio between 2 and 3 was 15.6

57 ntly, warfarin was continued to maintain the international normalized ratio between 2 and 3.5 (group

58 whom were receiving acenocoumarol and had an international normalized ratio between 2.0 and 3.0 durin

59 S-TIPS prognostic index (PI) score (based on international normalized ratio, bilirubin, and age) was

60 Liver-related blood parameters (international normalized ratio, bilirubin, aspartate ami

61 s reproduces the empirical equations for the International Normalized Ratio calibration (INR), as wel

62 Patients with poor international normalized ratio control (i.e., time in th

63 0 mg (twice daily) was cost-effective unless international normalized ratio control was excellent (ti

64 he risk of hemorrhage was high or quality of international normalized ratio control was poor (time in

65 ctive in moderate-risk AF populations unless international normalized ratio control was poor.

66 of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was

67 centers' and patients' predicted quality of international normalized ratio control.

68 mostatic efficacy from start of infusion and international normalized ratio correction (</=1.3) at 0.

69 End-Stage Liver Disease and age, bilirubin, international normalized ratio, creatinine scores), comp

70 , Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Dru

71 , Bleeding history or predisposition, Labile international normalized ratio, Elderly [>65 years], Dru

72 , bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol c

73 , bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol c

74 oke, bleeding predisposition/history, labile international normalized ratio, elderly, drugs/alcohol)

75 , Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol).

76 eding history or predisposition, labile INR [international normalized ratio], elderly, drugs/alcohol

77 International normalized ratio exhibited a positive adju

78 y an MTP goal directed by TEG or by CCA (ie, international normalized ratio, fibrinogen, platelet cou

79 concentrations of bilirubin and creatinine, international normalized ratio for prothrombin time (INR

80 The preprocedure mean international normalized ratio for prothrombin time was

81 to oral anticoagulation (as assessed by the international normalized ratio for prothrombin time).

82 irubin and creatinine concentrations and the international normalized ratio for the prothrombin time.

83 sodium levels] and MELD-XI [does not include international normalized ratio]) for endpoint events, de

84 age older than 65 years, a prothrombin time international normalized ratio greater than 1.1, alpha-f

85 hy affected 50% of subjects if defined as an international normalized ratio greater than 1.2 and 21%

86 normalized ratio greater than 1.5 but not an international normalized ratio greater than 1.2 identifi

87 Acute traumatic coagulopathy defined as an international normalized ratio greater than 1.2 was not

88 at least one organ system dysfunction and an international normalized ratio greater than 1.4 at basel

89 ing acute traumatic coagulopathy by using an international normalized ratio greater than 1.5 but not

90 e traumatic coagulopathy to patients with an international normalized ratio greater than 1.5 may yiel

91 , acute traumatic coagulopathy defined as an international normalized ratio greater than 1.5 was sign

92 r than 1.2 and 21% of subjects if defined by international normalized ratio greater than 1.5.

93 ional normalized ratio values (defined as an international normalized ratio > 1.5).

94 iciency (total bilirubin level > 10 mg/dL or international normalized ratio > 2) occurred in 6 patien

95 included adult patients on warfarin with an international normalized ratio >/=1.5 who received froze

96 serum creatinine level >3 mg/dL or oliguria; international normalized ratio >1.5 or transaminases >5

97 sociation with TIC as defined by laboratory (international normalized ratio >1.5) or clinical (transf

98 rauma-induced coagulopathy [(TIC), admission international normalized ratio >1.5].

99 y postoperative day 7 bilirubin >10 mg/dL or international normalized ratio >1.6), and graft failure.

100 re at a higher risk for overanticoagulation (international normalized ratio >4; P = 0.052), compared

101 There were fewer percentage international normalized ratios >/=4 and </=1.5 and seri

102 elet count < 150x10(3)/mm(3)), coagulopathy (International Normalized Ratio>2.0), and renal insuffici

103 e of continuous renal replacement therapy or international normalized ratio had no effect on clotting

104 1; test for trend across 4 categories of the international normalized ratio), history of coronary art

105 se (HR, 1.35; 95% CI, 1.04-1.75), and labile international normalized ratio (HR, 1.33; 95% CI, 1.04-1

106 .7% vs. 2.5%; p = NS) despite increasing the international normalized ratio in a dose-related fashion

107 nit mortality (p < .0001), particularly when international normalized ratio increased after intensive

108 0 days of warfarin, age > or = 80 years, and international normalized ratio (INR) > or = 4.0 were ass

109 P < 0.01), platelet <150 U/L (P < 0.01), and International Normalized Ratio (INR) >1.2 (P < 0.01).

110 Among warfarin-treated patients with international normalized ratio (INR) >5, we sought to de

111 merican guidelines accept IV tPA use with an international normalized ratio (INR) </= 1.7.

112 e recovery was reflected by normalization of International normalized ratio (INR) (80% of patients),

113 , 95% confidence interval [CI] = 1.35-3.21), international normalized ratio (INR) (P < 0.001, HR = 9.

114 ial fibrillation, it is unclear how baseline international normalized ratio (INR) affects the dosing

115 Before plasma transfusion, the median international normalized ratio (INR) and activated parti

116 We explored the relation between admission international normalized ratio (INR) and acute infarct v

117 uency of hematoma enlargement in relation to international normalized ratio (INR) and BP.

118 International normalized ratio (INR) and plasma warfarin

119 Data on international normalized ratio (INR) and platelet counts

120 Prothrombin time (PT) and the associated international normalized ratio (INR) are routinely teste

121 atment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0

122 rch has compared the measures of summarizing international normalized ratio (INR) control over time.

123 the therapeutic range of 2.0 to 3.0 for the international normalized ratio (INR) during the first 12

124 orrelates directly to duration and degree of international normalized ratio (INR) elevation above the

125 ts of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin tim

126 s the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0.

127 At 1 month international normalized ratio (INR) increased after RYG

128 arfarin on the baseline corrected AUC of the International Normalized Ratio (INR) increased by 2.8 ti

129 An elevated international normalized ratio (INR) increases the risk

130 substantial treatment by baseline laboratory international normalized ratio (INR) interaction effect

131 us tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, th

132 but effective management is complex, and the international normalized ratio (INR) is often outside th

133 However, the optimal international normalized ratio (INR) levels during RFA h

134 egistry-Get With the Guidelines by admission international normalized ratio (INR) levels: subtherapeu

135 e (AST), alanine aminotransferase (ALT), and international normalized ratio (INR) measurements on adm

136 yridamole 75 mg daily (n = 26) with a target international normalized ratio (INR) of 2 to 3 from June

137 < or = 5 mg and > 5 mg necessary to keep an international normalized ratio (INR) of 2.5 to 3.5, and

138 days 1 through 11 of therapy and to a target international normalized ratio (INR) of either 1.8 or 2.

139 cument the increased risk for stroke when an international normalized ratio (INR) of less than 2.0 is

140 In the patients for whom the international normalized ratio (INR) of prothrombin time

141 For patients on warfarin therapy, an international normalized ratio (INR) recall interval not

142 warfarin daily dosage needed to reach target international normalized ratio (INR) represented the mai

143 Analysis using international normalized ratio (INR) suggested a dose-re

144 g warfarin dose and the number of predefined international normalized ratio (INR) thresholds for each

145 An acute increase in international normalized ratio (INR) to >3.0 in patients

146 5th, 75th percentiles) time from most recent international normalized ratio (INR) to ICH was 13 days

147 We used the international normalized ratio (INR) to measure the inte

148 nts with CF-LVADs have suggested that target international normalized ratio (INR) values <2.5 (range,

149 However, these variants also affect early international normalized ratio (INR) values during warfa

150 nticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or gr

151 sed on genetic variables, clinical data, and international normalized ratio (INR) values.

152 Percent time in therapeutic range (TTR) and international normalized ratio (INR) variability both me

153 percent time in therapeutic range (TTR) and international normalized ratio (INR) variability predict

154 The international normalized ratio (INR) was absent in 3% of

155 outcome was the percentage of time that the international normalized ratio (INR) was in the therapeu

156 Prothrombin time international normalized ratio (INR) was measured routin

157 hen compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258

158 itamin K antagonist was recommended, and the international normalized ratio (INR) was not to be measu

159 s of interest: age <1 year, total bilirubin, international normalized ratio (INR), albumin, growth fa

160 (AST), day-1 lactate, day-3 bilirubin, day-3 international normalized ratio (INR), and day-7 AST were

161 ctivated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures

162 donor age (DnAge), serum creatinine (Creat), International Normalized Ratio (INR), and serum albumin

163 tracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for co

164 on control with warfarin, as assessed by the international normalized ratio (INR), is challenging.

165 ctivated partial thromboplastin time (aPTT), international normalized ratio (INR), platelet count and

166 injury versus alanine transaminase (ALT) and International Normalized Ratio (INR).

167 in time monitoring should be reported as the International Normalized Ratio (INR).

168 bilirubin and prothrombin time expressed as International Normalized Ratio (INR).

169 with LT or death: age, etiology; coma grade; international normalized ratio (INR); serum pH; body mas

170 ndrome: warfarin-associated supratherapeutic international normalized ratio (INR; median, 6.5) at ons

171 rcentage of time in the target range for the international normalized ratio (INR; target range, 2.0 t

172 (7.6%) were receiving therapeutic warfarin (international normalized ratio [INR] >/=2) and 8290 (8.8

173 l coagulation assessment than routine tests (international normalized ratio [INR] and platelet count)

174 alyzed altered prothrombin time (measured as international normalized ratio [INR]) after initiation o

175 s, response to therapy (as determined by the international normalized ratio [INR]), and bleeding even

176 Recommended therapeutic international normalized ratios (INRs) for oral anticoag

177 eparin, warfarin-associated supratherapeutic international normalized ratios (INRs), and evidence of

178 ted with vitamin K antagonists have unstable International Normalized Ratios (INRs), increasing the r

179 in patients on warfarin therapy with similar international normalized ratios (INRs).

180 with AF had thromboembolic events at higher international normalized ratios (INRs).

181 International normalized ratios less than 2.0 were not a

182 ith patients who often failed to meet target international normalized ratio level (HR: 3.53, 95% CI:

183 rin who consistently achieved minimum target international normalized ratio levels or those on acetyl

184 er, hypertriglyceridemic events and abnormal international normalized ratio levels were more common a

185 nd alanine aminotransferase, and prothrombin international normalized ratio; LR, 0.09; 95% CI, 0.03-0

186 After excluding 250 patients with international normalized ratio < 1.3 and/or missing data

187 ns (P = 0.012), coagulation status on POD 7 (international normalized ratio < 1.4; P = 0.027), and pr

188 ulation with NOACs versus those on warfarin (international normalized ratio <1.7) or not on anticoagu

189 idence interval, 1.51-6.51; P=0.002) and the international normalized ratio measured prior LT (OR=4.9

190 preoperative pulmonary testing and a higher international normalized ratio measured prior LT were as

191 ve class) to 100% (coronary risk assessment; international normalized ratio measured).

192 ass rates included coronary risk assessment, international normalized ratio measured, HbA1c measureme

193 3.4 [5.0] vs -7.8 [6.9]; P = .02), and worst international normalized ratio (median [interquartile ra

194 Model for End-Stage Liver Disease Excluding international normalized ratio (MELD-XI) score at the ti

195 perative temperature less than 95 degrees F, international normalized ratio more than 1.5, or a pH le

196 t cerebral edema and a higher posttransplant international normalized ratio (odds ratios and 95% conf

197 luded a prothrombin time of 15.4 seconds, an international normalized ratio of 1.2, and a partial thr

198 f warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that o

199 rction patients, warfarin therapy (at a mean international normalized ratio of 1.8) combined with low

200 The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 o

201 bo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients

202 to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin

203 linical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double

204 udies revealed a normal white-cell count, an international normalized ratio of more than 11, a prothr

205 to calculate the MELD score were available (international normalized ratio of prothrombin time, tota

206 rovides maximal protection against stroke at international normalized ratios of 2.0 to 3.0.

207 Elevated international normalized ratio on hospital admission is

208 .85; 95% confidence interval, 0.79-0.92) and international normalized ratio (OR, 1.45; 95% confidence

209 rial fibrillation (OR: 5.19), subtherapeutic international normalized ratio (OR: 7.37), increased cus

210 The international normalized ratio profile correlated poorly

211 ity (r=0.97), prothrombin time (r=0.77), and international normalized ratio (r=0.72) but less so with

212 on maintaining adequate time in therapeutic International Normalized Ratio range (TTR).

213 iated with the time spent above or below the international normalized ratio range.

214 Times in extreme international normalized ratio ranges of <1.5 and >4.0 w

215 Rapid international normalized ratio reduction was achieved in

216 in treatment is maintenance of a therapeutic international normalized ratio, regardless of the age of

217 Median international normalized ratio reversal was 11.8 hours w

218 Secondary outcomes included time to international normalized ratio reversal, hospital length

219 ed Kingdom End-Stage Liver Disease) included international normalized ratio, serum creatinine, biliru

220 The international normalized ratio should be tightly control

221 itoring, the difficulties in maintaining the international normalized ratio target (variable between

222 ring devices, patients can conduct their own international normalized ratio testing and dose adjustme

223 may yield greater returns than using a lower international normalized ratio threshold.

224 in time in critically ill patients using the international normalized ratio to standardize data and e

225 ables (hemoglobin, alkaline phosphatase, and international normalized ratio), together with important

226 oagulopathy (OR: 3.1, 95% CI: 1.7 to 5.8 per international normalized ratio unit), and in those recei

227 nsive care unit stay, but the pretransfusion international normalized ratio value varied widely.

228 care unit admissions, 30% developed abnormal international normalized ratio values (defined as an int

229 ies were minor and short-lived (73% of worst international normalized ratio values 1.6-2.5).

230 ong independent association between abnormal international normalized ratio values and greater intens

231 onist therapy can be complicated by unstable international normalized ratio values and patient-relate

232 Hemoglobin levels and international normalized ratio values were similar in pa

233 to 15% weekly dose changes for out-of-range International Normalized Ratio values.

234 (SD) base deficit was -9.8 (6.3), and median international normalized ratio was 1.3 (interquartile ra

235 The mean international normalized ratio was 1.4 in the warfarin g

236 Median (range) baseline international normalized ratio was 3.90 (1.8-20.0) for t

237 tients and 40% to nonbleeding patients whose international normalized ratio was normal or only modest

238 after warfarin had been stopped or when the international normalized ratio was subtherapeutic.

239 ion of total treatment time during which the international normalized ratio was within the therapeuti

240 nalysis, recipient's age and elevated pre-LT international normalized ratio were associated with incr

241 l thromboplastin time, prothrombin time, and international normalized ratio were reduced from warfari

242 Mean warfarin treatment was 1 year; mean international normalized ratios were 1.9 (IPAH) and 2.0

243 International normalized ratios were monitored using enc

244 0044) and took longer to reach a therapeutic international normalized ratio with rivaroxaban versus w

245 ges (P = 0.0002), spent less time with their international normalized ratio within the target range (

246 warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic ra